Universal flu vaccine

Influenza, commonly known as "the flu", is a serious disease that causes between 250,000 and 500,000 worldwide annual deaths, rising to millions in pandemic years. It can sometimes lead to pneumonia, either direct viral pneumonia or secondary bacterial pneumonia, even in persons who are usually very healthy. Because of the way it can modify proteins on its outer surface, influenza is constantly evolving. This means that vaccines quickly become useless and new versions are required each year.
However, researchers found that material on the inside was common to many strains of the virus. By targeting this core region – that never changes, even in new strains – it was hoped that a universal flu vaccine could be developed that would be effective against all current and future outbreaks.
A type of white blood cell known as CD8 – part of the body's immune system – was found to recognise proteins in the core. Using blood samples from human volunteers, taken during the 2009 pandemic, it was discovered that patients with higher levels of CD8 T-cells had milder symptoms and less chance of developing flu. By identifying the exact subtype of the immune system giving protection and which components of the virus it was attacking, researchers were able to develop a "blueprint" for a vaccine that could stimulate production of these T-cells.* Following further years of research, the vaccine is made publicly available by 2018.*